Cover Image
市場調查報告書

病毒性結膜炎 : 開發中產品分析

Viral Conjunctivitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 201009
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
病毒性結膜炎 : 開發中產品分析 Viral Conjunctivitis - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 33 Pages
簡介

病毒性結膜炎是常見的自限性疾病,一般是由於腺病毒引起。病毒性結膜炎發病後到紅眼期間傳染性強,通常維持10∼12天。前兆有眼睛發癢,淚眼,眼球充血,膿,對光過敏(角膜相關)等。治療有使用潤滑油,血管收縮藥,抗組織胺藥物等。

本報告提供病毒性結膜炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

病毒性結膜炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Adenovir Pharma AB
  • NanoViricides, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Shire Plc
  • Starpharma Holdings Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9662IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Viral Conjunctivitis - Overview
    • Viral Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Viral Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Viral Conjunctivitis - Companies Involved in Therapeutics Development
    • Adenovir Pharma AB
    • NanoViricides Inc
    • Panoptes Pharma GesmbH
    • Shire Plc
  • Viral Conjunctivitis - Drug Profiles
    • APD-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-514 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EKCCide-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OKG-0301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Viral Conjunctivitis - Dormant Projects
  • Viral Conjunctivitis - Discontinued Products
  • Viral Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
      • Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
      • May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Viral Conjunctivitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2017
  • Viral Conjunctivitis - Pipeline by NanoViricides Inc, H2 2017
  • Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H2 2017
  • Viral Conjunctivitis - Pipeline by Shire Plc, H2 2017
  • Viral Conjunctivitis - Dormant Projects, H2 2017
  • Viral Conjunctivitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Viral Conjunctivitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top